Comparison of Oxidative Stress and Inflammation Induced by Different Intravenous Iron Sucrose Similar Preparations in a Rat Model

Jorge Eduardo Toblli*, Gabriel Cao, Leda Oliveri and Margarita Angerosa

Laboratory of Experimental Medicine, Hospital Alemán, School of Medicine, University of Buenos Aires, Av. Pueyrredon 1640, (1118) Buenos Aires, Argentina

Abstract: Iron sucrose originator (ISORIG) has been used to treat iron deficiency and iron deficiency anemia for decades. Iron sucrose similars (ISSs) have recently entered the market. In this non-clinical study of non-anemic rats, five doses (40 mg iron/kg body weight) of six ISSs marketed in Asian countries, ISORIG or saline solution (control) were administered intravenously over four weeks to compare their toxicologic effects. Vasodilatory effects, impaired renal function and hepatic damage were only observed in the ISS groups. Significantly elevated serum iron and transferrin saturation levels were observed in the ISS groups suggesting a higher release of iron resulting in higher amounts of non-transferrin bound (free) iron compared to ISORIG. This might explain the elevated oxidative stress and increased levels of inflammatory markers and antioxidant enzymes in the liver, heart and kidneys of ISS-treated animals. Physico-chemical analyses showed that the molecular structure of most of the ISSs differed greatly from that of the ISORIG. These differences may be responsible for the organ damage and oxidative stress observed in the ISS groups. Significant differences were also found between different lots of a single ISS product. In contrast, polarographic analyses of three different ISORIG lots were identical, indicating that the molecular structure and thus the manufacturing process for ISORIG is highly consistent. Data from this study suggest that ISSs and ISORIG differ significantly. Therefore, before widespread use of these products it would be prudent to evaluate additional non-clinical and/or clinical data proving the safety, therapeutic equivalence and interchangeability of ISSs with ISORIG.

Keywords: Anemia, inflammation, iron deficiency, iron sucrose, iron sucrose similar, oxidative stress.

INTRODUCTION

Iron deficiency (ID) is one of the world’s most prevalent nutrient deficiencies [1]. It has various causes, such as increased iron demands due to blood loss, growth, pregnancy, inadequate dietary intake due to poor nutrition, and inadequate gastrointestinal absorption due to malabsorption or interference with drugs and food components. Because iron-containing enzymes are essential for all major metabolic processes, ID can lead to inadequate synthesis of these essential enzymes and thus to deleterious effects on cells and tissues. Untreated ID can lead to iron deficiency anemia (IDA), a condition in which the number of red blood cells (RBCs), the hemoglobin (Hb) level, and the volume of packed RBCs in the blood are below the normal values [2, 3]. IDA is an additional burden in numerous disease states including chronic heart failure (CHF), inflammatory bowel disease and chronic kidney disease (CKD) [4-9].

Iron supplementation is often necessary to manage ID with or without anemia. The key goal is to replenish body iron stores and, if present, correct the Hb deficit [2]. Although oral iron administration is the least expensive form of iron therapy [5], the intravenous (i.v.) route of iron administration has become more favored in recent years in many clinical settings due to the gastrointestinal intolerance, low iron delivery rates, limited absorption and prolonged iron store repletion times associated with oral iron supplements [10]. The iron preparations for i.v. administration that have been available already for several years include iron sucrose, sodium ferric gluconate, and low- and high-molecular weight iron dextran. Recently, preparations that allow rapid administration of high doses of iron, such as ferric carboxymaltose (available in various countries) and ferumoxytol (available in the USA), have been marketed worldwide. All iron complexes for i.v. administration consist of a polymeric iron(III)-oxyhydroxide core shielded by a carbohydrate shell [11, 12]. However, they vary widely in their physico-chemical properties, pharmacological activity, and side effects [11, 13, 14].

Despite the rapid recovery of the ID status in response to i.v. iron administration, there are potential risks associated with i.v. iron. Due to the risk of life-threatening/serious anaphylactic reactions associated with i.v. iron dextran, in particular high-molecular weight iron dextran, this form of iron therapy is not generally recommended [15-17]. Moreover, the more labile, low molecular weight compounds, such as ferric gluconate, release larger amounts of iron into the circulation generating non-transferrin bound iron (NTBI) [14, 18]. NTBI is taken up unspecifically by the liver, endocrine tissue and heart where it may catalyze a number of reactions that lead to oxidative stress and tissue damage [19, 20]. The extent of iron release into the circulation determines the maximum allowed single dose of an i.v. iron preparation to
minimize the amount of NTBI [21]. More stable iron complexes can be administered in higher doses.

Iron sucrose is an intravenous iron preparation that contains no dextran or its derivatives, and the associated incidence of allergic side effects has been shown to be rare [11, 22]. The iron sucrose originator (ISORIG, iron sucrose preparation, Venofer®, Vifor International, Switzerland) complex has been in clinical use for decades for the treatment of ID and IDA in a variety of clinical conditions [2]. In recent years, a number of new iron sucrose similar (ISS) preparations have entered the market. Their structures differ from that of the ISORIG complex due to different manufacturing processes [23]. These subtle structural differences may present a significant risk, raising potential concerns about the safety and efficacy of ISS preparations in clinical use. Non-clinical studies have indicated hemodynamic and functional differences between the ISORIG and ISS preparations and, in particular, a higher potential of ISSs to induce oxidative stress in kidneys, liver and heart [24, 25]. Additionally, in a recently published observational clinical study, switching the i.v. iron treatment of hemodialysis patients from ISORIG to an ISS led to a significant decrease in Hb levels and iron indices suggesting that the studied ISS preparation may not be therapeutically equivalent to ISORIG [26].

We previously established a non-clinical model that allows distinguishing between the potential of ISS preparations to induce oxidative stress in the liver, heart and kidneys [24, 25]. In the present study, we used this same model to compare the properties of six ISS preparations in the Asian market with those of the ISORIG complex.

METHODS

Physico-Chemical Analysis

Physico-chemical analyses were performed by the Quality Control Laboratory of Vifor (International) Ltd. (St. Gallen, Switzerland) on the samples of the ISS preparations. Molecular weight distribution was measured by gel permeation chromatography as described previously [11, 27]. The Fe(III)/Fe(II) reduction potentials were measured by polarography as described previously [11]. The turbidity point, pH and titratable alkalinity were assessed by methods described previously [27, 28].

Animals and Treatments

All experiments were approved by the Hospital Alemán Animal Care and the Teaching and Research Committee, and performed in accordance with the NIH Guide for the Care and Use of Laboratory Animals. Forty male and forty female 2-month-old non-anemic Sprague-Dawley rats (Laboratory of Experimental Medicine, Hospital Alemán, Buenos Aires, Argentina) weighing 200-220 g were randomized into eight groups (n = 10/group) with an equal male-female distribution. The control group received isotonic saline solution and the ISORIG group received iron sucrose [Venofer®, LOT 517100, Vifor (International), Switzerland]. The ISS groups received either ISSFERP (Ferplex®, SS, LOT H3797, Himont Pharmaceuticals, Lahore, Pakistan), ISSFERI (Ferijet, LOT 024-Y, Akson Pharmaceuticals, Azad Kashmir, Pakistan), ISSFERG (Ferosoft® S, LOT 6016, Hilton Pharma Ltd., Karachi, Pakistan), ISSENC1 (Encifer®, Emcure Pharmaceuticals Ltd., Pune, India), ISSmetics (Fe-Back, Nang-Kuang Pharmaceutical Co. Ltd., Tainan Hsien, Taiwan) or ISSIB (Fe-Lib, LOT AS015, Advanced International Pharmaceutical Nanotech Inc., Taiwan).

Rats were housed in metabolic cages in a temperature-controlled room (22 ± 2 °C) subject to 12 h light/dark cycles (07.00-19.00). All animals had free access to tap water and were fed standard rat chow (16-18% protein, Cooperación, Argentina) ad libitum throughout the study. Rats received a single i.v. dose by tail vein injection of the corresponding iron compound (40 mg/kg body weight) or control solution (equivalent volume) at the same time every 7 days for 4 weeks (a total of five administrations on days 0, 7, 14, 21 and 28). Treatment doses were adjusted each week according to the body weight of each animal.

Blood samples were obtained for biochemical assessment of Hb, serum iron and transferrin saturation (TSAT) 24 h after an i.v. iron treatment on days 1, 8, 15, 22 and 29. Urine was collected in each group for 24 h after each i.v. injection with methods described previously [29]. The rats were sacrificed on day 29 by subtotal exsanguination under anesthesia (sodium thiopental, 40 mg/kg body weight, intraperitoneal) according to institutional guidelines for animal care and use. Previously, blood samples were obtained for biochemical determination. The liver, heart and kidneys of each rat were perfused with ice cold saline solution through the abdominal aorta until they were free of blood and then removed for oxidative stress evaluation, microscopy and immunohisto-chemical study.

Blood Pressure Measurement

Systolic blood pressure (SBP) was measured by tail-cuff plethysmography at baseline (day 0) and 24 h after each i.v. iron administration (days 1, 8, 15, 22, and 29). Cuff pressure was determined by a Pneumatic Pulse Transducer using a Programmed electro-sphygmonanometer PE-300 (Narco Bio-Systems, Austin, Texas, USA); rats were restrained in a plastic chamber without anesthesia. Pulses were recorded on a Physiograph MK-IIIS (Narco Bio-Systems, Austin, Texas, USA) and a minimum of three measurements were taken at each session. The SBP was calculated as an average of the three readings [29, 30].

Biochemical Procedures

Blood samples were collected from the tail vein in capillary tubes for biochemical determination after 14 h of fasting. Hb concentration was determined by SYSMEX XT 1800i (Roche Diagnostic GmbH, Mannheim, Germany). Serum iron was determined by radial immunodiffusion (Diffu-Plate, Biocientifica S.A., Buenos Aires, Argentina) and TSAT was obtained using traditional chemical methods. Liver enzymes, including aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP), were assessed in the blood samples by colorimetric and ultraviolet (UV) methods using an Autoanalyzer Modular P800 with corresponding reagents (Roche Diagnostic GmbH, Mannheim, Germany). Aliquots of urine were assessed for creatinine with the enzymatic UV method (Randox Laboratories Ltd., Crumlin, Northern Ireland). Creatinine clearance (CrCl) was determined by the standard
formula, and proteinuria was determined using the sulfosalicylic acid method.

### Evaluation of Oxidative Stress Parameters in Liver, Heart and Kidney

Samples of the whole liver, heart and kidney were homogenized (1:3, w:v) in ice cold 0.25 M sucrose solution. Glutathione (GSH) levels were determined in the 10,000 g supernatant by methods described previously [31, 32]. Further samples of the corresponding perfused tissues were homogenized (1:10, w:v) in 0.05 M sodium phosphate buffer (pH 7.4) and used for the determination of malondialdehyde to evaluate lipid peroxidation by thiobarbituric acid reactive species (TBARS). The remaining homogenate was centrifuged at 4 °C for 15 min at 9,500 g and the supernatant was used to measure catalase activity. The remaining tissue samples were homogenized (1:3, w:v) in ice cold sucrose solution (0.25 M). The supernatant obtained after centrifugation at 105,000 g for 90 min was used to measure Cu, Zn superoxide dismutase (Cu, Zn-SOD) and glutathione peroxidase (GPx) activity. Enzyme units (U) were defined previously [14]. Specific activity was expressed as U/mg protein.

### Light Microscopy and Immunohistochemical Study

Decapsulated kidney, liver and heart samples were cut longitudinally, fixed in phosphate-buffered 10% formaldehyde (pH 7.2) and embedded in paraffin. Three-micron sections were cut and stained. All observations were made with a light microscope Nikon E400 (Nikon Instrument Group, Melville, New York, USA) [24, 33, 34].

Immunolabeling of specimens was carried out using a modified avidin-biotin-peroxidase technique (Vectorstain ABC kit, Universal Elite, Vector Laboratories, CA, USA) as described previously [14]. Tissue ferritin was quantified with antiferritin monoclonal antibody (Biogen, San Román, California, USA). Pro-inflammatory markers were quantified with monoclonal antibodies against rat tumor necrosis factor-alpha (TNF-α) (R&D Systems, Minneapolis, MN, USA) and interleukin-6 (IL6) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at dilutions of 1:50 and 1:100, respectively (PBS diluting agent) [29, 35].

### Morphometric Analysis

Histological sections were studied in each animal with an image analyzer (Image-Pro Plus version 4 for Windows, Media Cybernetics LP, Silver Spring, MD, USA) as described previously [14].

### Statistical Methods

Values are expressed as mean ± SD. All statistical analyses were performed using absolute values and processed through GraphPad Prism version 5.01 for Windows (GraphPad Software, Inc. San Diego, CA, USA). For parameters with a Gaussian distribution, comparisons among groups were performed using analysis of variance (ANOVA) and for parameters with a non-Gaussian distribution using Kruskal-Wallis test (non-parametric ANOVA) and Dunn’s multiple comparison test. A value of p<0.05 was considered significant.

### RESULTS

#### Physico-Chemical Analyses

The physico-chemical analyses of the studied ISS preparations showed clearly that, except for ISSFERP, these products do not comply with the specifications of ISSORIG [27]. All ISSs, except for ISSFERP, had lower titratable alkalinity and out of range turbidity point (Table 1). In addition, ISSFERI, ISSBACK, and ISSLIB had a very high molecular weight. ISSFERI and ISSFERO also had a lower pH

---

**Table 1.** Characteristics, pH, Titratable Alkalinity, Turbidity Point, and Molecular Weight of the Six Asian ISS Preparations Compared with the Originator Iron Sucrose (ISSORIG) and the Pharmacopeia (USP). (Studies Performed by the Quality Control Laboratory of Vifor (International), St. Gallen, Switzerland)

| Parameter | USP a | ISSORIG | ISSFERP | ISSFERI | ISSFERO | ISSENC1 | ISSENC1 | ISSBACK | ISSBACK | ISSLIB |
|-----------|-------|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| Lot       | -     | H3797   | 024-T   | LHA04003| LHA05005| F5097   | D5064   | A5015   |
| Characteristics | -     | Dark brown, opaque aqueous solution | Complies | Complies | Complies | Complies | Complies | Complies | Complies |
| pH        | 10.5-11.1 | 10.9 | 10.5 | 10.4 | 9.8 | 10.6 | 10.8 | 10.8 | 10.5 | 10.6 |
| Titratable alkalinity (ml) | 0.5-0.8 | 0.8 | 0.55 | 0.4 | 0.18 | 0.33 | 0.4 | 0.46 | 0.38 | 0.37 |
| Turbidity point | 4.4-5.3 | 4.9 | 5.1 | 9.7 | 4.2 | 5.8 | 6.4 | N/A b | N/A b | 5.33 |
| Mw (Da)   | 34,000-60,000 | 45,700 | 50,600 | 215,000 | 39,200 | 50,500 | 46,400 | 293,000 | 162,000 | 246,000 |
| Mn (Da)   | >24,000 | 33,900 | 36,100 | 85,200 | 31,300 | 35,100 | 34,200 | 175,000 | 93,300 | 151,000 |
| P         | ≤1.7   | 1.3    | 1.4    | 2.52   | 1.25   | 1.44   | 1.36   | 1.67   | 1.74   | 1.63   |

a [27] b Starting solution turbid
N/A, not available; Mw (Da), weight average molecular weight in Dalton; Mn (Da), number average molecular weight in Dalton; P = ratio Mw/Mn
than IS\textsubscript{CRD}. Interestingly, great variations in some of the physico-chemical parameters were also observed between the different lots of the two ISSs (ISS\textsubscript{ENC1} and ISS\textsubscript{BACK}) that were analyzed.

The reduction potentials were determined by polarography and are measured vs. Ag/AgCl 3M KCl, if not otherwise specified. The iron(III)/iron(II) reduction potentials varied considerably among the different investigated ISSs. The reduction potential of ISS\textsubscript{FERO} was the only one of the studied ISSs that complied with the reference value for iron sucrose and also the shape of its polarogram was found to be identical to that of IS\textsubscript{CRD} (Fig. 1). The reduction potentials of ISS\textsubscript{BACK} and ISS\textsubscript{LIB} were not determinable due to low solubility of these compounds. In addition, the shapes of the polarograms for these ISSs were different from that of IS\textsubscript{CRD}, confirming the dissimilarities between the structures of these ISSs and that of the IS\textsubscript{CRD} complex (Fig. 1). The reduction potentials of ISS\textsubscript{FERO} and ISS\textsubscript{ENC1} did not match the specifications for iron sucrose (-750 ± 50 mV) [27]. The polarogram of ISS\textsubscript{FERO} revealed two distinct Fe(III)/Fe(II) transitions at -495 and -765 mV. ISS\textsubscript{FERO} had a reduction potential of -566 mV, whereas ISS\textsubscript{ENC1} had different values depending on the analyzed lot (-565 and -534 mV for lot LHA04003 and LHA05005, respectively). In contrast, polarograms of three randomly chosen lots of ISS\textsubscript{CRD} had an identical shape and complied with the reference specification, reflecting the high consistency of the manufacturing process and thus the structure of the IS\textsubscript{CRD} complex (Fig. 1).

**Non-Clinical Study**

Throughout the non-clinical study, no significant differences were observed in Hb concentrations between the i.v. iron-treated and control groups, as expected for non-anemic rats (Table 2). Biochemical analysis revealed that serum iron concentration and TSAT levels were significantly elevated (p<0.01) in animals from the ISS groups and the IS\textsubscript{CRD} group compared to control group on days 1, 8 and 29 (Table 2). The IS\textsubscript{CRD} group showed significantly lower values (p<0.01) in both serum iron concentration and percentage TSAT compared to the ISS groups on days 1, 8 and 29.

All ISS groups (ISS\textsubscript{FERO}, ISS\textsubscript{FREL}, ISS\textsubscript{FREL}, ISS\textsubscript{ENC1}, ISS\textsubscript{BACK}, ISS\textsubscript{LIB}) presented a significant decrease in SBP throughout the study compared to the control and IS\textsubscript{CRD} groups (p<0.01) (Table 3); there were no significant differences between the ISS groups themselves.

CirC1 was significantly reduced in rats from all of the ISS groups on days 1, 8 and 29 compared with the IS\textsubscript{CRD} and control groups (p<0.01) (Table 4), whereas the values between the IS\textsubscript{CRD} and control group did not differ significantly. All ISS groups showed significant proteinuria on days 1, 8 and 29 (p<0.01) compared with the IS\textsubscript{CRD} and control groups, which showed no differences throughout the study (Table 4). Assessment of liver function showed that AST, ALT and ALP levels were significantly increased (p<0.01) in all ISS groups on days 1, 8 and 29 compared with IS\textsubscript{CRD} and control groups (Fig. 2A-C). Significant differences, although modest (p<0.05), were observed between the IS\textsubscript{CRD} group and the control group on days 1 and 8. However, there was no marked difference between these groups on day 29.

The liver, heart and kidney tissues of all the ISS groups showed a significant increase (p<0.01) in malondialdehyde (TBARS), catalase, GPx, and Cu, Zn-SOD levels and a significant decrease (p<0.01) in GSH level when compared with the IS\textsubscript{CRD} and control groups on day 29 (Fig. 3A-E).

The IS\textsubscript{CRD} group showed only modest non-significant increases in the levels of malondialdehyde, catalase, GPx, and Cu, Zn-SOD in the liver and a modest non-significant decrease in the GSH levels in the liver, heart and kidneys compared to the control group on day 29. Other oxidative stress parameters did not differ between the IS\textsubscript{CRD} group and the control group in heart or kidneys at the end of the study.

On day 29, microscopy studies of the liver showed significantly more (p<0.01) positive staining for iron (Prussian blue) in the Kupffer cells, sinusoidal epithelial cells and hepatocytes in all ISS groups compared to the IS\textsubscript{CRD} group. The IS\textsubscript{CRD} group had iron deposits only in the Kupffer cells and displayed a significantly (p<0.01) greater area for ferritin staining in the liver compared to the ISS and control groups (Fig. 5).

On day 29, cardiomyocytes of all ISS groups showed a significantly larger (p<0.01) area for iron staining (Prussian blue) compared to that of the cardiomyocytes of the IS\textsubscript{CRD} and control groups. Only small ferritin deposits were observed in all of the ISS groups. Therefore ferritin deposits were significantly larger (p<0.01) in the IS\textsubscript{CRD} group (Table 5).

A significant (p<0.01) positive staining for iron (Prussian blue) was detected in the proximal tubular epithelial cells of all the ISS groups compared with the IS\textsubscript{CRD} and control groups on day 29. The IS\textsubscript{CRD} group showed a larger area for ferritin deposits in the proximal tubular epithelial cells compared to all of the ISS and control groups (Table 5).

Upon completion of the experiments, the levels of both inflammatory markers TNF-α and IL6 were significantly increased (p<0.01) in the liver, heart and kidney samples of the ISS groups compared with the IS\textsubscript{CRD} and control groups (Figs 4 and 5).

**DISCUSSION**

The iron sucrose originator complex has been in clinical use for decades representing a good therapeutic option for correction of ID and IDA in more than 80 countries [2]. Together with erythropoiesis-stimulating agents it has become an integral part of IDA management associated with various clinical conditions. Clinical experience with IS\textsubscript{CRD} is based on patient exposure of more than 12 million patient years (as of 30 June 2011). IS\textsubscript{CRD} is regarded as a product with a good clinical profile [36, 37], particularly as it carries a low potential risk of hypersensitivity reactions [38].

Iron sucrose is a complex made of a polynuclear iron(III)-oxyhydroxide core stabilized by a sucrose ligand [39]. As such, it is a polymeric compound which belongs to the class of non-biological complex drugs and therefore is very different from conventional small molecule active pharmaceutical ingredients (APIs). Polymeric compounds are composed of a large number of molecules of slightly
different molecular weights and are characterized by a distinct molecular weight distribution. Thus, characterization of polymeric compounds requires a set of analytical methods different from those used for conventional APIs. Due to the complexity of the process to synthesize iron sucrose, the manufacturing process largely defines the quality of the product [23, 39].

Recently, a number of ISS preparations have entered the market [23-25]. However, little is known about their safety profile as non-clinical or clinical data are not largely available. In this study, the toxicologic effects of six ISS preparations marketed in Asian countries (ISSFERP, ISSFERI-

---

**Fig. (1).** Polarograms of (A) ISSFERP, (B) ISSBACK (Lot 5064), (C) ISSLIB, and (D-F) three randomly chosen lots of ISSORIG. (Studies performed by the Quality Control Laboratory of Vifor (International) Ltd., St. Gallen, Switzerland.)
Differences Between Intravenous Iron Sucrose Preparations in a Rat Model

Inflammation & Allergy - Drug Targets, 2012, Vol. 11, No. 1

Fig. (2). (A) Aspartate aminotransferase (AST), (B) alanine aminotransferase (ALT) and (C) alkaline phosphatase (ALP) after weekly i.v. administration (40 mg iron /kg body weight or equivalent volume) in the IS$_{ORIG}$- ISS and control groups over a 4-week period.

Table 2. Hemoglobin (Hb), Serum Iron and Transferrin Saturation (TSAT)

| Mean ± SD          | ISS$_{FERP}$ (n = 10) | ISS$_{FERI}$ (n = 10) | ISS$_{FERO}$ (n = 10) | ISS$_{ENCI}$ (n = 10) | ISS$_{BACK}$ (n = 10) | ISS$_{LIB}$ (n = 10) | ISS$_{ORIG}$ (n = 10) | Control (n = 10) |
|--------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------|
|                   | Day 1                  | Day 1                  | Day 1                  | Day 1                  | Day 1                  | Day 1                  | Day 1                  | Day 1            |
| Hb (g/dL)          | 15.8 ± 0.2             | 15.8 ± 0.1             | 16.0 ± 0.1             | 16.1 ± 0.1             | 15.9 ± 0.2             | 15.8 ± 0.2             | 15.9 ± 0.2             | 15.8 ± 0.5       |
| Serum iron (µg/dL) | 559.1 ± 60.2           | 563.2 ± 55.3           | 539.0 ± 59.1           | 542.2 ± 50.0           | 549.9 ± 47.1           | 555.1 ± 60.0           | 360.0 ± 42.0           | 309.9 ± 15.0*   |
| TSAT (%)           | 86.9 ± 4.3             | 90.0 ± 4.1             | 87.7 ± 5.0             | 86.8 ± 5.9             | 86.9 ± 6.0             | 89.2 ± 3.9             | 73.2 ± 6.2*             | 45.1 ± 3.8*     |
|                   | Day 8                  | Day 8                  | Day 8                  | Day 8                  | Day 8                  | Day 8                  | Day 8                  | Day 8            |
| Hb (g/dL)          | 16.2 ± 0.1             | 16.4 ± 0.2             | 16.3 ± 0.2             | 16.1 ± 0.1             | 16.4 ± 0.1             | 16.4 ± 0.2             | 15.9 ± 0.4             |                 |
| Serum iron (µg/dL) | 489.0 ± 52.0           | 500.0 ± 66.0           | 499.0 ± 58.0           | 488.3 ± 45.0           | 500.1 ± 32.0           | 479.9 ± 52.0           | 398.0 ± 33.0           | 318.0 ± 18.0*   |
| TSAT (%)           | 85.9 ± 3.0             | 87.0 ± 5.2             | 89.9 ± 6.1             | 89.4 ± 6.0             | 88.3 ± 4.9             | 88.2 ± 5.2             | 69.9 ± 5.5*             | 48.3 ± 5.9*     |
|                   | Day 29                 | Day 29                 | Day 29                 | Day 29                 | Day 29                 | Day 29                 | Day 29                 | Day 29           |
| Hb (g/dL)          | 16.4 ± 0.2             | 16.5 ± 0.2             | 16.5 ± 0.1             | 16.5 ± 0.2             | 16.5 ± 0.2             | 16.5 ± 0.2             | 16.0 ± 0.5             |                 |
| Serum iron (µg/dL) | 478.1 ± 45.2           | 458.9 ± 60.0           | 486.3 ± 43.0           | 453.7 ± 41.1           | 469.5 ± 56.2           | 487.9 ± 39.9           | 395.7 ± 21.0*           | 301.0 ± 10.8*   |
| TSAT (%)           | 84.4 ± 4.2             | 89.9 ± 6.1             | 88.9 ± 5.3             | 89.0 ± 5.7             | 84.8 ± 5.1             | 86.6 ± 4.4             | 70.1 ± 4.5*             | 47.2 ± 4.6*     |

*p < 0.01 versus all groups
p < 0.01 versus ISS$_{FERP}$, ISS$_{FERI}$, ISS$_{FERO}$, ISS$_{ENCI}$, ISS$_{BACK}$, ISS$_{LIB}$
Inflammation & Allergy - Drug Targets, 2012, Vol. 11, No. 1 Toblli et al.

Table 3. Systolic Blood Pressure (mean ± SD) After Weekly i.v. Administration (40 mg Iron/kg Body Weight or Equivalent Volume) in ISS, ISORIG and Control Groups Over a 4-Week Period

| Day | ISSFERP (n = 10) | ISSFERI (n = 10) | ISSFERO (n = 10) | ISSENC (n = 10) | ISSBACK (n = 10) | ISSLIB (n = 10) | ISORIG (n = 10) | Control (n = 10) |
|-----|------------------|------------------|------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| 0   | 118.1 ± 2.4      | 119.0 ± 2.9      | 118.1 ± 2.4      | 119.0 ± 2.9     | 118.1 ± 2.3     | 119.1 ± 2.9     | 118.9 ± 2.2     | 118.9 ± 1.9     |
| 1   | 112.3 ± 1.9      | 111.0 ± 0.1      | 112.3 ± 1.9      | 114.1 ± 1.9     | 112.3 ± 1.9     | 112.0 ± 1.9     | 116.2 ± 2.0*    | 120.2 ± 0.5*    |
| 8   | 111.4 ± 1.7      | 112.0 ± 3.1      | 114.7 ± 1.7      | 113.6 ± 3.1     | 114.7 ± 1.7     | 110.1 ± 3.1     | 117.8 ± 2.8*    | 119.8 ± 2.1*    |
| 15  | 112.6 ± 1.8      | 111.1 ± 2.4      | 114.9 ± 1.8      | 114.1 ± 2.4     | 116.8 ± 1.8     | 114.7 ± 2.4     | 118.0 ± 2.2*    | 120.3 ± 2.1*    |
| 22  | 113.7 ± 2.0      | 114.2 ± 2.5      | 114.5 ± 2.0      | 112.1 ± 2.5     | 114.5 ± 2.0     | 113.9 ± 2.5     | 119.4 ± 1.9*    | 120.3 ± 2.0*    |
| 29  | 115.1 ± 1.8      | 114.8 ± 3.0      | 113.6 ± 2.5      | 114.7 ± 2.6     | 113.7 ± 2.0     | 113.8 ± 3.0     | 121.2 ± 2.6*    | 122.1 ± 2.4*    |

*p < 0.01 versus all groups
#p < 0.01 versus ISSFERP, ISSFERI, ISSFERO, ISSENC, ISSBACK, ISSLIB

Table 4. Creatinine Clearance and Proteinuria After Weekly i.v. Administration (40 mg Iron/kg Body Weight or Equivalent Volume) in the ISS, ISORIG and Control Groups Over a 4-Week Period

| Day | ISSFERP (n = 10) | ISSFERI (n = 10) | ISSFERO (n = 10) | ISSENC (n = 10) | ISSBACK (n = 10) | ISSLIB (n = 10) | ISORIG (n = 10) | Control (n = 10) |
|-----|------------------|------------------|------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| CrCl|                  |                  |                  |                  |                  |                  |                 |                 |
| 1   | 2.4 ± 0.1        | 2.3 ± 0.1        | 2.4 ± 0.2        | 2.1 ± 0.1        | 2.2 ± 0.1        | 2.3 ± 0.2        | 2.7 ± 0.1*      | 2.8 ± 0.1*      |
| 8   | 3.3 ± 0.1        | 2.2 ± 0.1        | 2.3 ± 0.1        | 2.2 ± 0.2        | 2.3 ± 0.1        | 2.8 ± 0.1*      | 2.9 ± 0.1*      |                 |
| 29  | 2.1 ± 0.1        | 2.2 ± 0.1        | 2.2 ± 0.1        | 2.3 ± 0.2        | 2.1 ± 0.2        | 2.4 ± 0.2        | 2.7 ± 0.1*      | 2.9 ± 0.1*      |

*p < 0.01 versus all groups
#p < 0.01 versus ISSFERP, ISSFERI, ISSFERO, ISSENC, ISSBACK, ISSLIB

Proteinuria

| Day | ISSFERP (n = 10) | ISSFERI (n = 10) | ISSFERO (n = 10) | ISSENC (n = 10) | ISSBACK (n = 10) | ISSLIB (n = 10) | ISORIG (n = 10) | Control (n = 10) |
|-----|------------------|------------------|------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| 1   | 19.2 ± 5.5       | 22.1 ± 6.2       | 16.9 ± 7.1       | 18.5 ± 7.9      | 17.4 ± 5.8      | 19.9 ± 5.8      | 20.4 ± 1.3*     | 1.2 ± 2.0*      |
| 8   | 21.9 ± 6.6       | 26.3 ± 7.7       | 27.3 ± 9.9       | 33.2 ± 5.8      | 22.9 ± 4.9      | 25.1 ± 4.1      | 5.7 ± 2.4*      | 4.1 ± 2.1*      |
| 29  | 35.4 ± 7.0       | 31.8 ± 8.2       | 30.7 ± 5.9       | 39.4 ± 8.2      | 35.1 ± 5.8      | 29.8 ± 7.9      | 6.3 ± 3.0*      | 3.8 ± 3.0*      |

*p < 0.01 versus all groups
#p < 0.01 versus ISSFERP, ISSFERI, ISSFERO, ISSENC, ISSBACK, ISSLIB

sufficient to ensure a comparable safety and efficacy profile of these products [42].

In the present study, the results of the physico-chemical analysis of the investigated ISSs showed that only one of them, namely ISSFERP, complied with the USP values for iron sucrose. Within the other ISSs, significant fluctuations in the physico-chemical parameters from the reference values for iron sucrose were evident. In addition, differences in the physico-chemical parameters were also seen between the different lots of ISSENC and ISSBACK. Clearly, the manufacturing processes of these two ISSs are not well controlled and thus lead to products with variable structure, stability and quality. In contrast, the manufacturing process of ISORIG is highly consistent, as shown by the identical polarograms of three randomly chosen lots. The polarographic analysis does not only indicate the potential of a complex to undergo redox cycling (reduction potential), but it is also considered as a fingerprint for the structure of the complex. Lack of physico-chemical identity with the originator demonstrates that ISSFERI, ISSFERO, ISSENC, ISSBACK, and ISSLIB do not possess pharmaceutical equivalence to ISORIG.

According to the non-clinical analysis, initial observations of the effects of the ISS compounds on SBP revealed marked hypotension. This was evident throughout the 4-week study in all ISS-treated animals, whereas SBP in the ISORIG and control groups was not affected. The vasodilatory effects associated with ISS administration highlight a potentially significant risk factor for translation to clinical practice and are consistent with the hypotensive effects reported in animals receiving ISS preparations in previous studies [24, 25].

Renal function, explored by CrCl, was not affected in rats treated with ISORIG, but it was significantly reduced in the ISS groups. The reduced CrCl was accompanied by a marked proteinuria, indicating not only impaired renal function but also some disturbance in glomerular epithelial cells (podocytes) and tubular epithelial cells, in ISS-treated animals. As in our previous studies [24, 25], these results suggest that ISS preparations have more deleterious effects on the kidneys compared to the ISORIG compound. Also parallel to our previous studies, ISS induced hepatic damage was indicated by elevated levels of liver enzymes (ALT, AST and ALP) in the ISS groups compared to the ISORIG and control groups throughout the study [24, 25, 33]. The hepatic injury associated with elevated levels of liver enzymes in the blood may raise concerns regarding the use of ISS compounds in the clinical setting.
The stability of an iron complex depends on the exact structure of the complex and, in particular, on the interaction between the polynuclear iron(III)-hydroxide core and the surrounding carbohydrate [11]. As expected, in this study, all i.v. iron treated animals showed a significant increase in serum iron and TSAT levels. However, the administration of the ISS preparations resulted in significantly higher serum iron and TSAT levels than administration of the IS ORIG. Serum iron reflects the balance of iron flow in and out of the plasma pool [2, 43]. Therefore, higher serum iron levels induced by the ISS preparations suggest a quicker release of iron from these carbohydrate complexes causing transfer mechanisms of iron to be saturated, which leads to the generation of non-transferrin bound iron (NTBI). The more labile compounds release iron more quickly and to a greater extent, saturating transferrin, generating higher amounts of NTBI, and possibly causing oxidative stress, endothelial damage, inflammation and hemodynamic alterations [44].

Fig. (3). (A) Thiobarbituric acid reactive species (TBARS), (B) catalase, (C) Cu,Zn-superoxide dismutase (Cu,Zn-SOD), (D) glutathione peroxidase (GPx), (E) glutathione (GSH) in liver, heart and kidney homogenates after i.v. administration (40 mg iron /kg body weight or equivalent volume) in the IS ORIG, ISS and control groups on day 29.
NTBI is taken up unspecifically by the liver, endocrine tissue and heart where it may further catalyze reactions leading to oxidative stress and tissue damage [19, 20]. Therefore, it is not surprising that the markers for oxidative stress and the levels of antioxidant enzymes were significantly increased in the liver, heart and kidney tissues in all ISS-treated animals compared to the IS ORIG-treated animals and the control group throughout the study. Furthermore, oxidative stress can also increase the risk of endothelial damage and inflammation [44, 45]. The levels of both pro-inflammatory markers TNF-α and IL6 were substantially higher in the ISS groups relative to IS ORIG and control groups at the end of the study. These results further confirm that IS ORIG has a lower potential to induce oxidative stress and inflammation in this non-clinical model. From a clinical point of view, these findings may be important since i.v. iron therapy is often used to treat ID or IDA in CKD, CHF and cancer patients, who are already subject to increased levels of oxidative stress. This is particularly relevant for hemodialysis patients, who necessitate frequent administration of i.v. iron.

In vitro experiments have also shown differences among commonly used i.v. iron preparations. In particular, there is accumulating evidence that depending on the stability and the redox properties of the iron complex, iron preparations can influence cytokine activation, reactive oxygen species generation, and lymphocyte survival to different degrees [46-48].

In this study, the iron(III)/iron(II) reduction potentials of the different ISSs, except ISSFERP, showed great variations from the USP values for iron sucrose and that of IS ORIG. The reduction potentials of ISSFERD, ISSFERO and ISSENC1 were more positive than that of IS ORIG, suggesting that these ISS preparations may undergo redox cycling under physiological conditions and thus cause oxidative stress. Previous studies also showed that other ISSs with a more positive reduction potential than that of IS ORIG induced oxidative stress in an analogous non-clinical model [24, 25]. Interestingly, ISSFERI was found to exhibit two distinct reduction potentials whereas ISSENC1 had different reduction potentials depending on the analyzed lot.

Cellular uptake, transient storage and subsequent utilization of iron are influenced in part by the type of iron preparation administered and in part by the dosage, treatment regimen and physiological status of the patient [49]. Iron from the ideal iron preparation is transiently deposited in the reticuloendothelial system and not in the parenchyma of the liver [11]. IS ORIG shows exactly this pattern, with a more pronounced increase in iron and ferritin in the liver, and only a smaller increase relative to the control group in the heart and kidney. The presence of NTBI and oxidative stress in the livers of animals of the ISS groups was consistent with positive staining for iron not only in the Kupffer cells but also in the surrounding tissue. Accordingly, ferritin deposits, in particular in the liver, were reduced in the ISS groups suggesting that iron was stored in other cellular compartments rather than in the endogenous storage protein ferritin found predominantly in the liver.

The data from this study along with the results from three additional ISSs tested in two previously published studies [24, 25] show that various ISSs have slightly different toxicological patterns. In particular, the organs analyzed (liver, heart, and kidney) were not always affected to the same extent. For instance, most ISSs from this study showed a more pronounced effect on the kidneys (as seen from the proteinuria, IL6, iron and ferritin data), whereas significant differences in liver toxicity have been observed for two ISSs tested in a previous study [24].

Despite the significant differences that have been observed between IS ORIG and the investigated ISSs, the clinical relevance of the toxicological model used in this study and the significance of the results obtained require further discussion. The i.v. administration route adopted in this study is similar to clinical practice since iron sucrose can be given by both injection as well as infusion. However, the single iron doses used in the clinic are usually lower than those used in this study. Regarding oxidative stress, several clinical studies have investigated changes in biomarkers of oxidative stress after i.v. iron administration and demonstrated an inverse relation between the stability of the iron complexes and the induction of oxidative stress [46, 47-48].

Table 5. Prussian Blue Staining and Ferritin Immunostaining in the Liver, Heart and Kidney Samples of the Six Asian ISS Groups, the IS ORIG Group, and the Control Group on Day 29

| Mean ± SD | ISSFERP (n = 10) | ISSFERI (n = 10) | ISSFERO (n = 10) | ISSENC1 (n = 10) | ISSBACK (n = 10) | ISSLIB (n = 10) | IS ORIG (n = 10) | Control (n = 10) |
|-----------|-----------------|-----------------|-----------------|-----------------|-----------------|----------------|----------------|----------------|
| Prussian blue (% positive staining/area) | | | | | | | | |
| Liver | 6.8 ± 2.0 | 15.1 ± 3.2 | 14.6 ± 2.2 | 14.2 ± 2.6 | 14.7 ± 2.8 | 14.9 ± 1.8 | 7.4 ± 2.0* | 1.2 ± 0.5* |
| Heart | 4.1 ± 0.7 | 3.8 ± 0.6 | 4.0 ± 0.7 | 3.6 ± 0.8 | 3.9 ± 0.7 | 3.7 ± 0.8 | 1.1 ± 0.3* | 0.2 ± 0.1* |
| Kidney | 7.1 ± 1.0 | 6.2 ± 1.2 | 6.6 ± 1.5 | 6.4 ± 1.8 | 6.8 ± 1.3 | 6.3 ± 1.4 | 3.1 ± 0.8* | 1.3 ± 0.1* |
| Ferritin (% positive staining/area) | | | | | | | | |
| Liver | 7.3 ± 2.0 | 6.9 ± 1.7 | 6.8 ± 1.4 | 7.5 ± 2.0 | 7.5 ± 1.1 | 7.1 ± 2.0 | 15.2 ± 1.4* | 2.1 ± 0.6* |
| Heart | 1.8 ± 0.4 | 1.7 ± 0.3 | 1.7 ± 0.4 | 1.7 ± 0.5 | 1.4 ± 0.5 | 1.6 ± 0.6 | 3.1 ± 0.4* | 0.2 ± 0.1* |
| Kidney | 3.6 ± 0.5 | 3.0 ± 0.5 | 2.7 ± 0.7 | 3.3 ± 0.5 | 3.6 ± 0.3 | 3.4 ± 0.6 | 6.1 ± 0.7* | 0.2 ± 0.1* |

* p < 0.01 versus all groups
# p < 0.01 versus ISSFERP, ISSFERI, ISSFERO, ISSENC1, ISSBACK, ISSLIB
Differences Between Intravenous Iron Sucrose Preparations in a Rat Model

Inflammation & Allergy - Drug Targets, 2012, Vol. 11, No. 1

50-52]. Accordingly, differences in the physicochemical properties and stability of ISSs compared to IS<sub>ORIG</sub> as demonstrated in the present study may also be expected to affect oxidative stress levels in the clinical setting. In addition, differences observed in the present study in the distribution of iron that resulted in the deposition of iron in the parenchymal tissues instead of the reticuloendothelial system may lead to a decrease in the amount of iron that is available for effective erythropoiesis and, therefore, partly explain the recently published clinical observation of a lower efficacy of an ISS in maintaining Hb and iron status parameters in hemodialysis patients after the switch from IS<sub>ORIG</sub> [26].

**Fig. (4).** Bar chart and corresponding micrographs showing tumor necrosis factor-alpha (TNF-α) immunostaining in liver, heart and kidney samples taken from the IS<sub>ORIG</sub>, ISS and control groups on day 29.

**Fig. (5).** Bar chart and corresponding micrographs showing interleukin-6 (IL6) immunostaining in liver, heart and kidney samples taken from the IS<sub>ORIG</sub>, ISS and control groups on day 29.
Overall, the significant differences observed for most of the ISSs compared to the IS ORIG, raise potential safety concerns on the interchangeability of these i.v. iron preparations and suggest that careful non-clinical and clinical evaluations of the safety and efficacy of ISSs should be performed before exposing vulnerable patients to potential additional sources of oxidative stress and inflammation.

CONCLUSION

The results from this study support those of previous comparative non-clinical ISS studies highlighting the extent and severity of the effects that variations in manufacturing procedures for iron sucrose preparations can cause. The physico-chemical characterization demonstrated that five of the six studied ISS preparations do not comply with the specifications of the USP Monograph for iron sucrose injection. Differences of variable degree in the molecular structures of these compounds arise from variations in the manufacturing process and may be responsible for the toxic effects that were observed in this non-clinical model. In contrast, polarographic analyses of three different IS ORIG lots were identical and thus confirmed the high degree of consistency in the manufacturing process of IS ORIG. Interestingly, ISS FERP, which met the physico-chemical reference values for iron sucrose, induced an elevated level of oxidative stress compared to IS ORIG. Thus demonstrating that similar physico-chemical properties do not ensure similar toxicological effects. The reduced ability of the investigated ISSs to provide iron in the form that can be stored in ferritin, as well as the increased iron release indicated by higher oxidative stress marker levels, led to deleterious effects on hemodynamic, functional and inflammatory responses. In conclusion, all of the studied ISS preparations marketed in Asian countries showed different toxicological effects in rats compared to the iron sucrose originator and therefore, before administering such products in the clinical setting, it is suggested that therapeutic equivalence to the originator product ought to be proved to avoid exposing patients to potentially less safe preparations.

ABBREVIATIONS

| Symbol   | Description                      |
|----------|----------------------------------|
| ALP      | Alkaline phosphatase             |
| ALT      | Alanine aminotransferase         |
| AST      | Aspartate aminotransferase       |
| CHF      | Chronic heart failure            |
| CrCl     | Creatinine clearance             |
| Cu,Zn-SOD| Cu,Zn superoxide dismutase       |
| GPx      | Glutathione peroxidase           |
| GSH      | Glutathione                      |
| Hb       | Hemoglobin                       |
| i.v.     | Intravenous                      |
| ID       | Iron deficiency                  |
| IDA      | Iron deficiency anemia           |
| IL6      | Interleukin-6                    |
| IS ORIG  | Iron sucrose originator         |
| ISS      | Iron sucrose similar             |
| ISS BACK | Iron sucrose similar Fe-Back     |
| ISS ENC | Iron sucrose similar Encifer®    |
| ISS FERI | Iron sucrose similar Ferijet®   |
| ISS FERO | Iron sucrose similar Ferosoft®-S |
| ISS FERP | Iron sucrose similar Ferplex® SS |
| ISS LIB  | Iron sucrose similar Fe-Lib      |
| NTBI     | Non-transferrin bound iron       |
| RBC      | Red blood cell                   |
| SBP      | Systolic blood pressure          |
| TBARS    | Thiobarbituric acid reactive species |
| TNF-α    | Tumor necrosis factor-alpha      |
| TSAT     | Transferrin saturation           |
| USP      | The United States Pharmacopeia   |

CONFLICT OF INTEREST

Vifor (International) Ltd. financially supported this study but did not contribute to the study design. Professor Jorge E. Toblli has received research grants and consultancy fees from Vifor Pharma Ltd. The other authors have no conflicts of interest to declare.

ACKNOWLEDGEMENT

Scientific writing support was provided by Dr. Taija Koskenkorva-Frank [Vifor (International) Ltd.].

REFERENCES

[1] de Benoist, B; McLean, E.; Egli, I.; Cogswell, M. Worldwide prevalence of anaemia 1993-2005: WHO global database of anaemia, World Health Organisation: Geneva, 2008.
[2] Crichton R.; Danielson B.; Geisser P. Iron therapy With Special Emphasis on Intravenous Administration, 4th ed.; UNI-MED Verlag AG: Bremen, 2008.
[3] Hugh R.; Schaefer R. Iron Deficiency and Iron Deficiency Anaemia, Thieme Medical Publishers: New York, 2006.
[4] Afzali, B.; Goldsmith, D.J. Intravenous iron therapy in renal failure: friend and foe? J. Nephrol., 2004, 17, 487-495.
[5] Alleyne, M.; Horne, M.K.; Miller, J.L. Individualized treatment for iron-deficiency anaemia in adults. Am. J. Med., 2003, 116(Suppl. 7A), 44S-49S.
[6] Jacobs, P.; Johnson, G.; Wood, L. Oral iron therapy in human subjects, comparative absorption between ferrous salts and iron polymaltose. J. Med., 1984, 15, 367-377.
[7] Nissenson, A.R.; Charytan, C. Controversies in iron management. Kidney Int., 2003, 64(Suppl. 87), S64-S71.
[8] Silverberg, D.S.; Wexler, D.; Blum, M.; Iaina, A. The cardio renal anemia syndrome: correcting anemia in patients with resistant congestive heart failure can improve both cardiac and renal function and reduce hospitalizations. Clin. Nephrol., 2003, 60(Suppl 1), S93-102.
[9] Wilson, A.; Reyes, E.; Ofman, J. Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. Am. J. Med., 2004, 116(Suppl 7A), 44S-49S.
[10] Johnson, D.W. Intravenous versus oral iron supplementation in peritoneal dialysis patients. Perit. Dial. Int., 2007, 27(Suppl 2), S255-S260.
[11] Geisser, P.; Baer, M.; Schaub, E. Structure/histotoxicity relationship of parenteral iron preparations. Drug Res., 1992, 42, 1439-1452.
Differences Between Intravenous Iron Sucrose Preparations in a Rat Model

Macdougall, I.C. Intravenous administration of iron in epoetin-treated haemodialysis patients–which drugs, which regimen? Nephrol. Dial. Transplant., 2000, 15, 1743-1745.

Macdougall, I.C. Strategies for iron supplementation: oral versus intravenous. Kidney Int., 1999, 55(Suppl 69), S61-S66.

Toblli, J.E.; Cao, G.; Oliveri, L.; Angerosa, M. Comparison of the renal, cardiovascular and hepatic toxicity data of original intravenous iron compounds. Nephrol. Dial. Transplant., 2010, 25, 3631-3640.

Chertow, G.M.; Mason, P.D.; Vaage-Nilsen, O.; Ahlmen, J. Update on adverse drug events associated with parenteral iron. Nephrol. Dial. Transplant., 2006, 21, 378-382.

Faich, G.; Strobus, J. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextran. Am. J. Kidney Dis., 1999, 33, 464-470.

Locatelli, F.; Alajama, P.; Bárány, P.; Canaud, B.; Carrera, F.; Eckardt, K.U.; Hörl, W.H.; Macdougall I.C.; Macleod, A.; Wieck, A.; Cameron, S. European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol. Dial. Transplant., 2004, 19 (Suppl 2), ii-47.

Temes, N.; Scheiber-Mojdehkar, B.; Landgraf, G.; Goldenberg, H.; Sturm, B. Iron availability and complex stability of iron hydroxyethyl starch and iron dextran a comparative in vitro study with liver cells and macrophages. Nephrol. Dial. Transplant., 2007, 22, 2824-2830.

Andrews, N.C.; Schmidt, P.J. Iron homeostasis. Annu. Rev. Physiol., 2007, 69, 69-85.

Evans, R.W.; Rafique, R.; Zarea, A.; Rapisarda, C.; Cammack, R.; Evans, P.J.; Porter, J.B.; Hider, R.C. Nature of non-transferrin-bound iron: studies on iron citrate complexes and thalassemic sera. J. Biol. Inorg. Chem., 2008, 13, 57-74.

Zanen, A.L.; Adriaansen, H.J.; van Bommel, E.F.; Posthuma, R.; Th de Jong, G.M. ‘Oversaturation’ of transferrin after intravenous ferric gluconate (Ferrlecit®) in haemodialysis patients. Nephrol. Dial. Transplant., 1996, 11, 820-824.

Michael, B.; Coyne, D.W.; Fishbane, S.; Folkert, V.; Lynn, R.; Nissensohn, A.R.; Agarwal, R.; Eschbach, J.W.; Fadem, S.Z.; Trout, J.R.; Strobus, J.; Warnock, D.G. Ferrlecit Publication Committee. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int., 2002, 61, 1830-1839.

Schellekens, H.; Klinge, E.; Muhlebach, S.; Brin, J.F.; Storm, G.; Crommelyn, D.J. The therapeutic equivalence of iron sucrose and ferric gluconate. Regul. Toxicol. Pharmacol., 2011, 59, 176-183.

Toblli, J.E.; Cao, G.; Oliveri, L.; Angerosa, M. Differences between original intravenous iron sucrose and iron sucrose similar Generis®, and potential implications. Nephrol. Hypert., 2006, 53-63.

Rottenburg, J.; Kadri, A.; Leonard, E.; Dansaert, A.; Lafuma, A. Do two intravenous iron sucrose preparations have the same efficacy? Nephrol. Dial. Transplant., 2011, 26, 3262-3267.

United States Pharmacopeial Convention. Iron Sucrose Injection. Official monograph in: The United States Pharmacopeia. United States Pharmacopeial Convention: Rockville, 2008, 31, 2449-2451.

Danielson, B.G. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J. Am. Soc. Nephrol., 2004, 13(Suppl 2), S93-S98.

Toblli, J.E.; Stella, I.; de Cavanagh, E.; Angerosa, M.; Inserra, F.; Ferder, L. Eналаприл prevents tubulointerstitial lesions by hyperoxaluria. Hypertension, 1999, 33, 225-231.

Yamakoshi, K.; Rolfe, P.; Murphy, C. Current developments in non-invasive measurement of arterial blood pressure. J. Biomed. Eng., 1988, 10, 130-137.

Akerboom, T.P.; Sies, H. Assay of glutathione, glutathione disulfide, and glutathione mixed disulfides in biological samples. Methods Enzymol., 1981, 7, 373-382.

Rossi, R.; Cardaiolo, E.; Scaloni, A.; Amiconi, G.; Di Simplicio, P. Thiol groups in proteins as endogenous reductants to determine glutathione-protein mixed disulfides in biological systems. Biochim. Biophys. Acta, 1995, 1245, 230-238.

Toblli, J.E.; Cao, G.; Oliveri, L.; Elba, V. Inflammatory response of generic iron sucrose complex preparations in kidney, liver and heart of normal rats. Nephrol. Dial. Transplant., 2006, 21, iv160.

Toblli, J.E.; Munoz, M.C.; Cao, G.; Mella, J.; Perea, L.; Mastai, R. ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. Obesity (Silver Spring), 2008, 16, 770-776.

Toblli, J.E.; Cao, G.; DeRosa, G.; Forcarda, P. Reduced cardiac expression of plasmoglobin activator inhibitor 1 and transforming growth factor beta1 in obese Zucker rats by perindopril. Heart, 2005, 91, 80-86.

Kolsgaard, S.; Simonov, S.; Simonenkov, V.; Dudas, L.V.; Karnafl, W.; Garcia, L.C.; Sambuelli, A.M.; DaHaens, G.; Gasche, C. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am. J. Gastroenterol., 2008, 103, 1182-1192.

Schroeder, O.; Mickisch, O.; Seidler, U.; de Weerth, A.; Dignass, A.U.; Herfarth, H.; Reinshagen, M.; Schreiber, S.; Junge, U.; Schwott, M.; Stein, J. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease–a randomized, controlled, open-label, multicenter study. Am. J. Gastroenterol., 2005, 100, 2593-2599.

Bailie, G.R. Differences in spontaneously reported hypersensitivity and serious adverse events for intravenous iron preparations: comparison of Europe and North America. Drug Res., 2011, 61, 267-275.

Geisser, P. Safety and efficacy of iron(III)-hydroxide polymaltose complex i a review of over 25 years experience. Drug Res., 2007, 57, 439-452.

Meier, T.; Schropp, P.; Pater, C.; Leoni, A.L.; Khov-Tran, V.V.; Elford, P. Physicochemical and toxicological characterization of a new generic iron sucrose preparation. Drug Res. 2011, 61, 112-119.

Toblli, J.E.; Cao, G.; Giani, J.; Dominici, F.; Angerosa, M. Different effects of European iron sucrose similar preparations and originator iron sucrose on nitrosative stress, apoptosis, oxidative stress, biochemical and inflammatory markers in rats. XVIII ERA-EDTA Congress, 2011, abstract Su0028.

European Medicines Agency. Reflection paper on non-clinical studies for generic nanoparticle iron medicinal product applications. 2011. Available from: http://www.ema.europa.eu/ docu/en_GB/document_library/Scientific_guideline/2011/04/WC50105048.pdf [Accessed 17 Aug 2011].

Van Wyck, D.B.; Anderson, J.; Johnson, K. Labile iron in parenteral iron formulations: a quantitative and comparative study. Nephrol. Dial. Transplant., 2004, 19, 561-565.

Fishbane, S. Safety in iron management. Am. J. Kidney Dis., 2003, 41, 18-26.

Kanitkarasari, A.E.; Georgiou, N.A.; Visseren, F.L.; van Kats-Renaud, H.; van Asbeck, B.S.; Marx, J.J. Endothelial activation and induction of monocyte adhesion by nontransferrin-bound iron present in human sera. FASEB J., 2006, 20, 353-355.

Pai, A.B.; Boyd, A.V.; McQuade, C.R.; Harford, A.; Noreenberg, J.P.; Zager, P.G. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis. Pharmacotherapy, 2007, 27, 343-350.

Pai, A.B.; Conner, T.; McQuade, C.R.; Olp, J.; Hicks, P. Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose. Biomol Lett. 2011, 24, 603-613.

Gupta, A.; Zhuo, J.; Zha, J.; Reddy, S.; Olp, J.; Pai, A. Effect of different intravenous iron preparations on lymphocyte intracellular reactive oxygen species generation and population survival. BMC Nephrol., 2010, 11, 16-20.

Caperna, T.J.; Failla, M.L.; Steele, N.C.; Richards, M.P. Accumulation and metabolism of iron-dextran by hepatocytes, Kupffer cells and endothelial cells in the neonatal pig liver. J. Nutr., 1987, 117, 312-320.

Stefansson, B.V.; Haraldsson, B.; Nilsson, U. Acute oxidative stress following intravenous iron injection in patients on chronic hemodialysis: a comparison of iron-sucrose and iron-dextran. Nephron Clin. Pract., 2011, 118, e249-256.

Inflammation & Allergy - Drug Targets, 2012, Vol. 11, No. 1 77
Michelis, R.; Sela, S.; Kristal, B. Intravenous iron-gluconate during haemodialysis modifies plasma beta2-microglobulin properties and levels. *Nephrol. Dial. Transplant.*, **2005**, *20*, 1963-1969.

Borawska, J.; Gozdziakiewicz, J.; Abramowicz, P.; Naumnik, B.; Mysliwiec, M. Endothelial injury markers with high-dose intravenous iron therapy in renal failure. *Clin. Appl. Thromb. Hemost.*, **2004**, *10*, 403-406.